nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilutamide—prostate cancer—urinary bladder cancer	0.381	1	CtDrD
Nilutamide—POR—urinary bladder cancer	0.289	1	CbGaD
Nilutamide—POR—Mitomycin—urinary bladder cancer	0.213	0.823	CbGbCtD
Nilutamide—POR—Doxorubicin—urinary bladder cancer	0.0298	0.115	CbGbCtD
Nilutamide—AR—scrotum—urinary bladder cancer	0.00551	0.291	CbGeAlD
Nilutamide—CYP2C8—Fluorouracil—urinary bladder cancer	0.00506	0.0196	CbGbCtD
Nilutamide—CYP2C8—Etoposide—urinary bladder cancer	0.00423	0.0164	CbGbCtD
Nilutamide—CYP2C9—Fluorouracil—urinary bladder cancer	0.00353	0.0137	CbGbCtD
Nilutamide—CYP2C9—Cisplatin—urinary bladder cancer	0.003	0.0116	CbGbCtD
Nilutamide—AR—penis—urinary bladder cancer	0.00249	0.131	CbGeAlD
Nilutamide—CYP2C19—urine—urinary bladder cancer	0.00153	0.0809	CbGeAlD
Nilutamide—CYP2C9—urine—urinary bladder cancer	0.00119	0.0627	CbGeAlD
Nilutamide—POR—prostate gland—urinary bladder cancer	0.001	0.053	CbGeAlD
Nilutamide—POR—seminal vesicle—urinary bladder cancer	0.00085	0.0448	CbGeAlD
Nilutamide—POR—urethra—urinary bladder cancer	0.000673	0.0355	CbGeAlD
Nilutamide—AR—prostate gland—urinary bladder cancer	0.000594	0.0313	CbGeAlD
Nilutamide—AR—seminal vesicle—urinary bladder cancer	0.000502	0.0265	CbGeAlD
Nilutamide—POR—vagina—urinary bladder cancer	0.000496	0.0262	CbGeAlD
Nilutamide—AR—epithelium—urinary bladder cancer	0.000436	0.023	CbGeAlD
Nilutamide—AR—smooth muscle tissue—urinary bladder cancer	0.00042	0.0222	CbGeAlD
Nilutamide—AR—renal system—urinary bladder cancer	0.000405	0.0214	CbGeAlD
Nilutamide—AR—urethra—urinary bladder cancer	0.000397	0.021	CbGeAlD
Nilutamide—CYP2C8—renal system—urinary bladder cancer	0.000327	0.0173	CbGeAlD
Nilutamide—AR—female reproductive system—urinary bladder cancer	0.000324	0.0171	CbGeAlD
Nilutamide—POR—lymph node—urinary bladder cancer	0.000321	0.0169	CbGeAlD
Nilutamide—AR—vagina—urinary bladder cancer	0.000293	0.0155	CbGeAlD
Nilutamide—CYP2C19—vagina—urinary bladder cancer	0.000272	0.0143	CbGeAlD
Nilutamide—CYP2C8—female reproductive system—urinary bladder cancer	0.000262	0.0138	CbGeAlD
Nilutamide—CYP2C8—vagina—urinary bladder cancer	0.000237	0.0125	CbGeAlD
Nilutamide—CYP2C9—female reproductive system—urinary bladder cancer	0.000233	0.0123	CbGeAlD
Nilutamide—AR—lymph node—urinary bladder cancer	0.00019	0.01	CbGeAlD
Nilutamide—AR—Regulation of Androgen receptor activity—CREBBP—urinary bladder cancer	7.18e-05	0.00539	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—CCNE1—urinary bladder cancer	7.1e-05	0.00533	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—GSTO2—urinary bladder cancer	7.03e-05	0.00528	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—NAT1—urinary bladder cancer	7.03e-05	0.00528	CbGpPWpGaD
Nilutamide—Malaise—Etoposide—urinary bladder cancer	7.01e-05	0.00178	CcSEcCtD
Nilutamide—Body temperature increased—Thiotepa—urinary bladder cancer	6.98e-05	0.00178	CcSEcCtD
Nilutamide—Abdominal pain—Thiotepa—urinary bladder cancer	6.98e-05	0.00178	CcSEcCtD
Nilutamide—Anorexia—Fluorouracil—urinary bladder cancer	6.96e-05	0.00177	CcSEcCtD
Nilutamide—Leukopenia—Etoposide—urinary bladder cancer	6.96e-05	0.00177	CcSEcCtD
Nilutamide—CYP2C8—Metapathway biotransformation—GSTO2—urinary bladder cancer	6.94e-05	0.00521	CbGpPWpGaD
Nilutamide—Oedema—Cisplatin—urinary bladder cancer	6.92e-05	0.00176	CcSEcCtD
Nilutamide—AR—Androgen receptor signaling pathway—NCOR1—urinary bladder cancer	6.89e-05	0.00517	CbGpPWpGaD
Nilutamide—Cardiac failure—Doxorubicin—urinary bladder cancer	6.86e-05	0.00175	CcSEcCtD
Nilutamide—Loss of consciousness—Etoposide—urinary bladder cancer	6.83e-05	0.00174	CcSEcCtD
Nilutamide—Cough—Etoposide—urinary bladder cancer	6.78e-05	0.00173	CcSEcCtD
Nilutamide—Blood creatinine increased—Epirubicin—urinary bladder cancer	6.78e-05	0.00172	CcSEcCtD
Nilutamide—CYP2C9—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	6.74e-05	0.00506	CbGpPWpGaD
Nilutamide—Insomnia—Gemcitabine—urinary bladder cancer	6.72e-05	0.00171	CcSEcCtD
Nilutamide—Hypertension—Etoposide—urinary bladder cancer	6.71e-05	0.00171	CcSEcCtD
Nilutamide—Gastrointestinal haemorrhage—Doxorubicin—urinary bladder cancer	6.69e-05	0.0017	CcSEcCtD
Nilutamide—Hyperhidrosis—Cisplatin—urinary bladder cancer	6.69e-05	0.0017	CcSEcCtD
Nilutamide—Paraesthesia—Gemcitabine—urinary bladder cancer	6.67e-05	0.0017	CcSEcCtD
Nilutamide—Dry skin—Epirubicin—urinary bladder cancer	6.63e-05	0.00169	CcSEcCtD
Nilutamide—CYP2C19—Biological oxidations—GSTZ1—urinary bladder cancer	6.62e-05	0.00497	CbGpPWpGaD
Nilutamide—Dyspnoea—Gemcitabine—urinary bladder cancer	6.62e-05	0.00169	CcSEcCtD
Nilutamide—Chest pain—Etoposide—urinary bladder cancer	6.62e-05	0.00168	CcSEcCtD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—TERT—urinary bladder cancer	6.62e-05	0.00497	CbGpPWpGaD
Nilutamide—Insomnia—Fluorouracil—urinary bladder cancer	6.61e-05	0.00168	CcSEcCtD
Nilutamide—Anorexia—Cisplatin—urinary bladder cancer	6.6e-05	0.00168	CcSEcCtD
Nilutamide—Paraesthesia—Fluorouracil—urinary bladder cancer	6.56e-05	0.00167	CcSEcCtD
Nilutamide—Discomfort—Etoposide—urinary bladder cancer	6.54e-05	0.00166	CcSEcCtD
Nilutamide—CYP2C19—Metapathway biotransformation—GSTZ1—urinary bladder cancer	6.53e-05	0.0049	CbGpPWpGaD
Nilutamide—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	6.52e-05	0.00166	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—TSC1—urinary bladder cancer	6.52e-05	0.00489	CbGpPWpGaD
Nilutamide—Dyspnoea—Fluorouracil—urinary bladder cancer	6.51e-05	0.00166	CcSEcCtD
Nilutamide—Decreased appetite—Gemcitabine—urinary bladder cancer	6.46e-05	0.00164	CcSEcCtD
Nilutamide—CYP2C8—Biological oxidations—UGT2B7—urinary bladder cancer	6.43e-05	0.00483	CbGpPWpGaD
Nilutamide—Dyspepsia—Fluorouracil—urinary bladder cancer	6.43e-05	0.00164	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	6.41e-05	0.00163	CcSEcCtD
Nilutamide—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	6.38e-05	0.00162	CcSEcCtD
Nilutamide—Constipation—Gemcitabine—urinary bladder cancer	6.35e-05	0.00162	CcSEcCtD
Nilutamide—Pain—Gemcitabine—urinary bladder cancer	6.35e-05	0.00162	CcSEcCtD
Nilutamide—Decreased appetite—Fluorouracil—urinary bladder cancer	6.35e-05	0.00162	CcSEcCtD
Nilutamide—CYP2C8—Metapathway biotransformation—UGT2B7—urinary bladder cancer	6.35e-05	0.00476	CbGpPWpGaD
Nilutamide—Asthenia—Thiotepa—urinary bladder cancer	6.34e-05	0.00161	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	6.31e-05	0.0016	CcSEcCtD
Nilutamide—CYP2C19—Biological oxidations—GSTO2—urinary bladder cancer	6.28e-05	0.00471	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—NAT1—urinary bladder cancer	6.28e-05	0.00471	CbGpPWpGaD
Nilutamide—Blood creatinine increased—Doxorubicin—urinary bladder cancer	6.27e-05	0.0016	CcSEcCtD
Nilutamide—Influenza—Epirubicin—urinary bladder cancer	6.25e-05	0.00159	CcSEcCtD
Nilutamide—Pruritus—Thiotepa—urinary bladder cancer	6.25e-05	0.00159	CcSEcCtD
Nilutamide—Pain—Fluorouracil—urinary bladder cancer	6.25e-05	0.00159	CcSEcCtD
Nilutamide—Paraesthesia—Cisplatin—urinary bladder cancer	6.22e-05	0.00158	CcSEcCtD
Nilutamide—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	6.21e-05	0.00158	CcSEcCtD
Nilutamide—CYP2C19—Metapathway biotransformation—GSTO2—urinary bladder cancer	6.19e-05	0.00465	CbGpPWpGaD
Nilutamide—Dyspnoea—Cisplatin—urinary bladder cancer	6.17e-05	0.00157	CcSEcCtD
Nilutamide—Erectile dysfunction—Methotrexate—urinary bladder cancer	6.15e-05	0.00157	CcSEcCtD
Nilutamide—Dry skin—Doxorubicin—urinary bladder cancer	6.14e-05	0.00156	CcSEcCtD
Nilutamide—Hyperhidrosis—Etoposide—urinary bladder cancer	6.13e-05	0.00156	CcSEcCtD
Nilutamide—Feeling abnormal—Gemcitabine—urinary bladder cancer	6.12e-05	0.00156	CcSEcCtD
Nilutamide—Angina pectoris—Epirubicin—urinary bladder cancer	6.09e-05	0.00155	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	6.06e-05	0.00455	CbGpPWpGaD
Nilutamide—Anorexia—Etoposide—urinary bladder cancer	6.05e-05	0.00154	CcSEcCtD
Nilutamide—Diarrhoea—Thiotepa—urinary bladder cancer	6.04e-05	0.00154	CcSEcCtD
Nilutamide—CYP2C9—Biological oxidations—GSTZ1—urinary bladder cancer	6.04e-05	0.00453	CbGpPWpGaD
Nilutamide—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	6.03e-05	0.00153	CcSEcCtD
Nilutamide—Decreased appetite—Cisplatin—urinary bladder cancer	6.02e-05	0.00153	CcSEcCtD
Nilutamide—Feeling abnormal—Fluorouracil—urinary bladder cancer	6.02e-05	0.00153	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	6.02e-05	0.00452	CbGpPWpGaD
Nilutamide—Pneumonia—Methotrexate—urinary bladder cancer	5.99e-05	0.00152	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	5.98e-05	0.00152	CcSEcCtD
Nilutamide—CYP2C9—Metapathway biotransformation—GSTZ1—urinary bladder cancer	5.96e-05	0.00447	CbGpPWpGaD
Nilutamide—Depression—Methotrexate—urinary bladder cancer	5.94e-05	0.00151	CcSEcCtD
Nilutamide—Pain—Cisplatin—urinary bladder cancer	5.92e-05	0.00151	CcSEcCtD
Nilutamide—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	5.9e-05	0.0015	CcSEcCtD
Nilutamide—Body temperature increased—Gemcitabine—urinary bladder cancer	5.87e-05	0.00149	CcSEcCtD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—CDK4—urinary bladder cancer	5.86e-05	0.0044	CbGpPWpGaD
Nilutamide—Dizziness—Thiotepa—urinary bladder cancer	5.84e-05	0.00149	CcSEcCtD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—ESR1—urinary bladder cancer	5.84e-05	0.00438	CbGpPWpGaD
Nilutamide—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	5.81e-05	0.00148	CcSEcCtD
Nilutamide—CYP2C8—Biological oxidations—CYP4B1—urinary bladder cancer	5.79e-05	0.00435	CbGpPWpGaD
Nilutamide—Influenza—Doxorubicin—urinary bladder cancer	5.79e-05	0.00147	CcSEcCtD
Nilutamide—Body temperature increased—Fluorouracil—urinary bladder cancer	5.77e-05	0.00147	CcSEcCtD
Nilutamide—CYP2C19—Biological oxidations—UGT2B7—urinary bladder cancer	5.74e-05	0.00431	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—GSTO2—urinary bladder cancer	5.73e-05	0.0043	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—NAT1—urinary bladder cancer	5.73e-05	0.0043	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—CYP4B1—urinary bladder cancer	5.71e-05	0.00429	CbGpPWpGaD
Nilutamide—Sweating—Methotrexate—urinary bladder cancer	5.71e-05	0.00145	CcSEcCtD
Nilutamide—Feeling abnormal—Cisplatin—urinary bladder cancer	5.71e-05	0.00145	CcSEcCtD
Nilutamide—AR—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	5.7e-05	0.00428	CbGpPWpGaD
Nilutamide—Paraesthesia—Etoposide—urinary bladder cancer	5.7e-05	0.00145	CcSEcCtD
Nilutamide—Haematuria—Methotrexate—urinary bladder cancer	5.68e-05	0.00145	CcSEcCtD
Nilutamide—AR—FOXA1 transcription factor network—EP300—urinary bladder cancer	5.68e-05	0.00426	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—UGT2B7—urinary bladder cancer	5.66e-05	0.00425	CbGpPWpGaD
Nilutamide—Weight decreased—Epirubicin—urinary bladder cancer	5.66e-05	0.00144	CcSEcCtD
Nilutamide—Dyspnoea—Etoposide—urinary bladder cancer	5.66e-05	0.00144	CcSEcCtD
Nilutamide—CYP2C9—Metapathway biotransformation—GSTO2—urinary bladder cancer	5.65e-05	0.00424	CbGpPWpGaD
Nilutamide—Hyperglycaemia—Epirubicin—urinary bladder cancer	5.64e-05	0.00144	CcSEcCtD
Nilutamide—Angina pectoris—Doxorubicin—urinary bladder cancer	5.64e-05	0.00143	CcSEcCtD
Nilutamide—AR—Coregulation of Androgen receptor activity—CDKN2A—urinary bladder cancer	5.62e-05	0.00422	CbGpPWpGaD
Nilutamide—Vomiting—Thiotepa—urinary bladder cancer	5.62e-05	0.00143	CcSEcCtD
Nilutamide—Pneumonia—Epirubicin—urinary bladder cancer	5.61e-05	0.00143	CcSEcCtD
Nilutamide—Rash—Thiotepa—urinary bladder cancer	5.57e-05	0.00142	CcSEcCtD
Nilutamide—Dermatitis—Thiotepa—urinary bladder cancer	5.56e-05	0.00142	CcSEcCtD
Nilutamide—Headache—Thiotepa—urinary bladder cancer	5.53e-05	0.00141	CcSEcCtD
Nilutamide—Decreased appetite—Etoposide—urinary bladder cancer	5.51e-05	0.0014	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Etoposide—urinary bladder cancer	5.48e-05	0.00139	CcSEcCtD
Nilutamide—Body temperature increased—Cisplatin—urinary bladder cancer	5.47e-05	0.00139	CcSEcCtD
Nilutamide—Pain—Etoposide—urinary bladder cancer	5.43e-05	0.00138	CcSEcCtD
Nilutamide—Constipation—Etoposide—urinary bladder cancer	5.43e-05	0.00138	CcSEcCtD
Nilutamide—Urinary tract infection—Epirubicin—urinary bladder cancer	5.42e-05	0.00138	CcSEcCtD
Nilutamide—AR—Notch-mediated HES/HEY network—EP300—urinary bladder cancer	5.39e-05	0.00404	CbGpPWpGaD
Nilutamide—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	5.38e-05	0.00137	CcSEcCtD
Nilutamide—Sweating—Epirubicin—urinary bladder cancer	5.35e-05	0.00136	CcSEcCtD
Nilutamide—Asthenia—Gemcitabine—urinary bladder cancer	5.33e-05	0.00136	CcSEcCtD
Nilutamide—Haematuria—Epirubicin—urinary bladder cancer	5.32e-05	0.00135	CcSEcCtD
Nilutamide—Urinary tract disorder—Methotrexate—urinary bladder cancer	5.28e-05	0.00134	CcSEcCtD
Nilutamide—Pruritus—Gemcitabine—urinary bladder cancer	5.26e-05	0.00134	CcSEcCtD
Nilutamide—Nausea—Thiotepa—urinary bladder cancer	5.25e-05	0.00133	CcSEcCtD
Nilutamide—Urethral disorder—Methotrexate—urinary bladder cancer	5.24e-05	0.00133	CcSEcCtD
Nilutamide—CYP2C9—Biological oxidations—UGT2B7—urinary bladder cancer	5.24e-05	0.00393	CbGpPWpGaD
Nilutamide—Weight decreased—Doxorubicin—urinary bladder cancer	5.23e-05	0.00133	CcSEcCtD
Nilutamide—Feeling abnormal—Etoposide—urinary bladder cancer	5.23e-05	0.00133	CcSEcCtD
Nilutamide—Hyperglycaemia—Doxorubicin—urinary bladder cancer	5.22e-05	0.00133	CcSEcCtD
Nilutamide—Pneumonia—Doxorubicin—urinary bladder cancer	5.19e-05	0.00132	CcSEcCtD
Nilutamide—Gastrointestinal pain—Etoposide—urinary bladder cancer	5.19e-05	0.00132	CcSEcCtD
Nilutamide—CYP2C19—Biological oxidations—CYP4B1—urinary bladder cancer	5.17e-05	0.00388	CbGpPWpGaD
Nilutamide—Pruritus—Fluorouracil—urinary bladder cancer	5.17e-05	0.00132	CcSEcCtD
Nilutamide—CYP2C9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	5.16e-05	0.00388	CbGpPWpGaD
Nilutamide—Visual impairment—Methotrexate—urinary bladder cancer	5.15e-05	0.00131	CcSEcCtD
Nilutamide—AR—Nongenotropic Androgen signaling—HRAS—urinary bladder cancer	5.14e-05	0.00386	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDH1—urinary bladder cancer	5.13e-05	0.00385	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—CREBBP—urinary bladder cancer	5.12e-05	0.00384	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—CYP4B1—urinary bladder cancer	5.1e-05	0.00383	CbGpPWpGaD
Nilutamide—Diarrhoea—Gemcitabine—urinary bladder cancer	5.08e-05	0.00129	CcSEcCtD
Nilutamide—Rhinitis—Epirubicin—urinary bladder cancer	5.02e-05	0.00128	CcSEcCtD
Nilutamide—Body temperature increased—Etoposide—urinary bladder cancer	5.02e-05	0.00128	CcSEcCtD
Nilutamide—Abdominal pain—Etoposide—urinary bladder cancer	5.02e-05	0.00128	CcSEcCtD
Nilutamide—Urinary tract infection—Doxorubicin—urinary bladder cancer	5.01e-05	0.00128	CcSEcCtD
Nilutamide—Diarrhoea—Fluorouracil—urinary bladder cancer	5e-05	0.00127	CcSEcCtD
Nilutamide—Hypoaesthesia—Epirubicin—urinary bladder cancer	4.98e-05	0.00127	CcSEcCtD
Nilutamide—Asthenia—Cisplatin—urinary bladder cancer	4.97e-05	0.00126	CcSEcCtD
Nilutamide—Sweating—Doxorubicin—urinary bladder cancer	4.95e-05	0.00126	CcSEcCtD
Nilutamide—Urinary tract disorder—Epirubicin—urinary bladder cancer	4.94e-05	0.00126	CcSEcCtD
Nilutamide—Oedema peripheral—Epirubicin—urinary bladder cancer	4.93e-05	0.00125	CcSEcCtD
Nilutamide—Haematuria—Doxorubicin—urinary bladder cancer	4.92e-05	0.00125	CcSEcCtD
Nilutamide—Urethral disorder—Epirubicin—urinary bladder cancer	4.91e-05	0.00125	CcSEcCtD
Nilutamide—CYP2C8—Arachidonic acid metabolism—GPX1—urinary bladder cancer	4.9e-05	0.00368	CbGpPWpGaD
Nilutamide—AR—Regulation of Androgen receptor activity—EP300—urinary bladder cancer	4.89e-05	0.00367	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	4.85e-05	0.00364	CbGpPWpGaD
Nilutamide—Dizziness—Fluorouracil—urinary bladder cancer	4.83e-05	0.00123	CcSEcCtD
Nilutamide—Visual impairment—Epirubicin—urinary bladder cancer	4.82e-05	0.00123	CcSEcCtD
Nilutamide—AR—Regulation of Androgen receptor activity—SRC—urinary bladder cancer	4.76e-05	0.00357	CbGpPWpGaD
Nilutamide—AR—Coregulation of Androgen receptor activity—CCND1—urinary bladder cancer	4.75e-05	0.00356	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—CREBBP—urinary bladder cancer	4.75e-05	0.00356	CbGpPWpGaD
Nilutamide—Diarrhoea—Cisplatin—urinary bladder cancer	4.74e-05	0.00121	CcSEcCtD
Nilutamide—AR—Androgen receptor signaling pathway—RB1—urinary bladder cancer	4.73e-05	0.00355	CbGpPWpGaD
Nilutamide—Alopecia—Methotrexate—urinary bladder cancer	4.73e-05	0.0012	CcSEcCtD
Nilutamide—Vomiting—Gemcitabine—urinary bladder cancer	4.72e-05	0.0012	CcSEcCtD
Nilutamide—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	4.71e-05	0.00354	CbGpPWpGaD
Nilutamide—Rash—Gemcitabine—urinary bladder cancer	4.68e-05	0.00119	CcSEcCtD
Nilutamide—Dermatitis—Gemcitabine—urinary bladder cancer	4.68e-05	0.00119	CcSEcCtD
Nilutamide—Headache—Gemcitabine—urinary bladder cancer	4.65e-05	0.00118	CcSEcCtD
Nilutamide—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	4.65e-05	0.00349	CbGpPWpGaD
Nilutamide—Vomiting—Fluorouracil—urinary bladder cancer	4.64e-05	0.00118	CcSEcCtD
Nilutamide—Rhinitis—Doxorubicin—urinary bladder cancer	4.64e-05	0.00118	CcSEcCtD
Nilutamide—Hypoaesthesia—Doxorubicin—urinary bladder cancer	4.61e-05	0.00117	CcSEcCtD
Nilutamide—Rash—Fluorouracil—urinary bladder cancer	4.61e-05	0.00117	CcSEcCtD
Nilutamide—Dermatitis—Fluorouracil—urinary bladder cancer	4.6e-05	0.00117	CcSEcCtD
Nilutamide—Headache—Fluorouracil—urinary bladder cancer	4.58e-05	0.00116	CcSEcCtD
Nilutamide—Urinary tract disorder—Doxorubicin—urinary bladder cancer	4.57e-05	0.00116	CcSEcCtD
Nilutamide—Oedema peripheral—Doxorubicin—urinary bladder cancer	4.56e-05	0.00116	CcSEcCtD
Nilutamide—Asthenia—Etoposide—urinary bladder cancer	4.55e-05	0.00116	CcSEcCtD
Nilutamide—Urethral disorder—Doxorubicin—urinary bladder cancer	4.54e-05	0.00116	CcSEcCtD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—urinary bladder cancer	4.53e-05	0.0034	CbGpPWpGaD
Nilutamide—Back pain—Methotrexate—urinary bladder cancer	4.5e-05	0.00115	CcSEcCtD
Nilutamide—Pruritus—Etoposide—urinary bladder cancer	4.49e-05	0.00114	CcSEcCtD
Nilutamide—Visual impairment—Doxorubicin—urinary bladder cancer	4.46e-05	0.00114	CcSEcCtD
Nilutamide—Alopecia—Epirubicin—urinary bladder cancer	4.42e-05	0.00113	CcSEcCtD
Nilutamide—Nausea—Gemcitabine—urinary bladder cancer	4.41e-05	0.00112	CcSEcCtD
Nilutamide—Vomiting—Cisplatin—urinary bladder cancer	4.4e-05	0.00112	CcSEcCtD
Nilutamide—CYP2C19—Arachidonic acid metabolism—GPX1—urinary bladder cancer	4.37e-05	0.00328	CbGpPWpGaD
Nilutamide—Rash—Cisplatin—urinary bladder cancer	4.37e-05	0.00111	CcSEcCtD
Nilutamide—Dermatitis—Cisplatin—urinary bladder cancer	4.36e-05	0.00111	CcSEcCtD
Nilutamide—Diarrhoea—Etoposide—urinary bladder cancer	4.34e-05	0.0011	CcSEcCtD
Nilutamide—Nausea—Fluorouracil—urinary bladder cancer	4.34e-05	0.0011	CcSEcCtD
Nilutamide—Ill-defined disorder—Methotrexate—urinary bladder cancer	4.32e-05	0.0011	CcSEcCtD
Nilutamide—Anaemia—Methotrexate—urinary bladder cancer	4.3e-05	0.0011	CcSEcCtD
Nilutamide—AR—Androgen receptor signaling pathway—RHOA—urinary bladder cancer	4.29e-05	0.00322	CbGpPWpGaD
Nilutamide—Tension—Epirubicin—urinary bladder cancer	4.28e-05	0.00109	CcSEcCtD
Nilutamide—Nervousness—Epirubicin—urinary bladder cancer	4.23e-05	0.00108	CcSEcCtD
Nilutamide—Back pain—Epirubicin—urinary bladder cancer	4.21e-05	0.00107	CcSEcCtD
Nilutamide—Malaise—Methotrexate—urinary bladder cancer	4.2e-05	0.00107	CcSEcCtD
Nilutamide—Dizziness—Etoposide—urinary bladder cancer	4.2e-05	0.00107	CcSEcCtD
Nilutamide—Leukopenia—Methotrexate—urinary bladder cancer	4.17e-05	0.00106	CcSEcCtD
Nilutamide—Nausea—Cisplatin—urinary bladder cancer	4.11e-05	0.00105	CcSEcCtD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—urinary bladder cancer	4.1e-05	0.00308	CbGpPWpGaD
Nilutamide—Alopecia—Doxorubicin—urinary bladder cancer	4.09e-05	0.00104	CcSEcCtD
Nilutamide—Cough—Methotrexate—urinary bladder cancer	4.06e-05	0.00103	CcSEcCtD
Nilutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	4.06e-05	0.00305	CbGpPWpGaD
Nilutamide—Ill-defined disorder—Epirubicin—urinary bladder cancer	4.04e-05	0.00103	CcSEcCtD
Nilutamide—Vomiting—Etoposide—urinary bladder cancer	4.03e-05	0.00103	CcSEcCtD
Nilutamide—Anaemia—Epirubicin—urinary bladder cancer	4.03e-05	0.00102	CcSEcCtD
Nilutamide—Rash—Etoposide—urinary bladder cancer	4e-05	0.00102	CcSEcCtD
Nilutamide—Dermatitis—Etoposide—urinary bladder cancer	4e-05	0.00102	CcSEcCtD
Nilutamide—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	3.99e-05	0.00299	CbGpPWpGaD
Nilutamide—Headache—Etoposide—urinary bladder cancer	3.97e-05	0.00101	CcSEcCtD
Nilutamide—Chest pain—Methotrexate—urinary bladder cancer	3.96e-05	0.00101	CcSEcCtD
Nilutamide—Tension—Doxorubicin—urinary bladder cancer	3.96e-05	0.00101	CcSEcCtD
Nilutamide—Malaise—Epirubicin—urinary bladder cancer	3.93e-05	0.001	CcSEcCtD
Nilutamide—Discomfort—Methotrexate—urinary bladder cancer	3.92e-05	0.000997	CcSEcCtD
Nilutamide—Nervousness—Doxorubicin—urinary bladder cancer	3.92e-05	0.000996	CcSEcCtD
Nilutamide—Syncope—Epirubicin—urinary bladder cancer	3.91e-05	0.000994	CcSEcCtD
Nilutamide—Leukopenia—Epirubicin—urinary bladder cancer	3.9e-05	0.000993	CcSEcCtD
Nilutamide—Back pain—Doxorubicin—urinary bladder cancer	3.9e-05	0.000992	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	3.85e-05	0.00289	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—NAT2—urinary bladder cancer	3.85e-05	0.00289	CbGpPWpGaD
Nilutamide—Loss of consciousness—Epirubicin—urinary bladder cancer	3.83e-05	0.000975	CcSEcCtD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—urinary bladder cancer	3.82e-05	0.00287	CbGpPWpGaD
Nilutamide—Cough—Epirubicin—urinary bladder cancer	3.8e-05	0.000968	CcSEcCtD
Nilutamide—CYP2C8—Metapathway biotransformation—NAT2—urinary bladder cancer	3.8e-05	0.00285	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	3.79e-05	0.00284	CbGpPWpGaD
Nilutamide—Nausea—Etoposide—urinary bladder cancer	3.77e-05	0.000959	CcSEcCtD
Nilutamide—Hypertension—Epirubicin—urinary bladder cancer	3.76e-05	0.000957	CcSEcCtD
Nilutamide—Ill-defined disorder—Doxorubicin—urinary bladder cancer	3.74e-05	0.000952	CcSEcCtD
Nilutamide—Anaemia—Doxorubicin—urinary bladder cancer	3.73e-05	0.000948	CcSEcCtD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—urinary bladder cancer	3.71e-05	0.00279	CbGpPWpGaD
Nilutamide—Chest pain—Epirubicin—urinary bladder cancer	3.71e-05	0.000944	CcSEcCtD
Nilutamide—Hyperhidrosis—Methotrexate—urinary bladder cancer	3.67e-05	0.000935	CcSEcCtD
Nilutamide—Discomfort—Epirubicin—urinary bladder cancer	3.67e-05	0.000933	CcSEcCtD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—CDKN1A—urinary bladder cancer	3.66e-05	0.00275	CbGpPWpGaD
Nilutamide—Malaise—Doxorubicin—urinary bladder cancer	3.64e-05	0.000925	CcSEcCtD
Nilutamide—Dry mouth—Epirubicin—urinary bladder cancer	3.63e-05	0.000923	CcSEcCtD
Nilutamide—Anorexia—Methotrexate—urinary bladder cancer	3.62e-05	0.000922	CcSEcCtD
Nilutamide—Syncope—Doxorubicin—urinary bladder cancer	3.62e-05	0.00092	CcSEcCtD
Nilutamide—Leukopenia—Doxorubicin—urinary bladder cancer	3.61e-05	0.000918	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—ATM—urinary bladder cancer	3.58e-05	0.00268	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—CDK4—urinary bladder cancer	3.56e-05	0.00267	CbGpPWpGaD
Nilutamide—Oedema—Epirubicin—urinary bladder cancer	3.56e-05	0.000905	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—ESR1—urinary bladder cancer	3.55e-05	0.00266	CbGpPWpGaD
Nilutamide—Loss of consciousness—Doxorubicin—urinary bladder cancer	3.54e-05	0.000902	CcSEcCtD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—EP300—urinary bladder cancer	3.52e-05	0.00264	CbGpPWpGaD
Nilutamide—Cough—Doxorubicin—urinary bladder cancer	3.52e-05	0.000895	CcSEcCtD
Nilutamide—AR—Androgen receptor signaling pathway—CCND1—urinary bladder cancer	3.51e-05	0.00264	CbGpPWpGaD
Nilutamide—Shock—Epirubicin—urinary bladder cancer	3.5e-05	0.00089	CcSEcCtD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—EP300—urinary bladder cancer	3.49e-05	0.00262	CbGpPWpGaD
Nilutamide—Hypertension—Doxorubicin—urinary bladder cancer	3.48e-05	0.000886	CcSEcCtD
Nilutamide—CYP2C19—Biological oxidations—NAT2—urinary bladder cancer	3.44e-05	0.00258	CbGpPWpGaD
Nilutamide—Hyperhidrosis—Epirubicin—urinary bladder cancer	3.44e-05	0.000875	CcSEcCtD
Nilutamide—Insomnia—Methotrexate—urinary bladder cancer	3.44e-05	0.000875	CcSEcCtD
Nilutamide—Chest pain—Doxorubicin—urinary bladder cancer	3.43e-05	0.000873	CcSEcCtD
Nilutamide—Paraesthesia—Methotrexate—urinary bladder cancer	3.41e-05	0.000868	CcSEcCtD
Nilutamide—AR—Androgen receptor signaling pathway—CDKN1A—urinary bladder cancer	3.4e-05	0.00255	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—NAT2—urinary bladder cancer	3.39e-05	0.00255	CbGpPWpGaD
Nilutamide—Discomfort—Doxorubicin—urinary bladder cancer	3.39e-05	0.000863	CcSEcCtD
Nilutamide—Anorexia—Epirubicin—urinary bladder cancer	3.39e-05	0.000863	CcSEcCtD
Nilutamide—AR—Androgen receptor signaling pathway—PTEN—urinary bladder cancer	3.39e-05	0.00254	CbGpPWpGaD
Nilutamide—Dyspnoea—Methotrexate—urinary bladder cancer	3.39e-05	0.000862	CcSEcCtD
Nilutamide—Dry mouth—Doxorubicin—urinary bladder cancer	3.36e-05	0.000854	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	3.35e-05	0.00252	CbGpPWpGaD
Nilutamide—Dyspepsia—Methotrexate—urinary bladder cancer	3.34e-05	0.000851	CcSEcCtD
Nilutamide—Decreased appetite—Methotrexate—urinary bladder cancer	3.3e-05	0.000841	CcSEcCtD
Nilutamide—Oedema—Doxorubicin—urinary bladder cancer	3.29e-05	0.000837	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	3.28e-05	0.000835	CcSEcCtD
Nilutamide—Pain—Methotrexate—urinary bladder cancer	3.25e-05	0.000827	CcSEcCtD
Nilutamide—Shock—Doxorubicin—urinary bladder cancer	3.24e-05	0.000824	CcSEcCtD
Nilutamide—AR—Androgen receptor signaling pathway—EP300—urinary bladder cancer	3.23e-05	0.00243	CbGpPWpGaD
Nilutamide—Insomnia—Epirubicin—urinary bladder cancer	3.22e-05	0.000818	CcSEcCtD
Nilutamide—Paraesthesia—Epirubicin—urinary bladder cancer	3.19e-05	0.000813	CcSEcCtD
Nilutamide—Hyperhidrosis—Doxorubicin—urinary bladder cancer	3.18e-05	0.000809	CcSEcCtD
Nilutamide—Dyspnoea—Epirubicin—urinary bladder cancer	3.17e-05	0.000807	CcSEcCtD
Nilutamide—AR—Androgen receptor signaling pathway—SRC—urinary bladder cancer	3.14e-05	0.00236	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	3.14e-05	0.00235	CbGpPWpGaD
Nilutamide—Anorexia—Doxorubicin—urinary bladder cancer	3.14e-05	0.000798	CcSEcCtD
Nilutamide—Feeling abnormal—Methotrexate—urinary bladder cancer	3.13e-05	0.000797	CcSEcCtD
Nilutamide—Dyspepsia—Epirubicin—urinary bladder cancer	3.13e-05	0.000797	CcSEcCtD
Nilutamide—Gastrointestinal pain—Methotrexate—urinary bladder cancer	3.11e-05	0.000791	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—RB1—urinary bladder cancer	3.1e-05	0.00232	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	3.09e-05	0.00232	CbGpPWpGaD
Nilutamide—Decreased appetite—Epirubicin—urinary bladder cancer	3.09e-05	0.000787	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—CDH1—urinary bladder cancer	3.09e-05	0.00232	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—HPGDS—urinary bladder cancer	3.08e-05	0.00231	CbGpPWpGaD
Nilutamide—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	3.07e-05	0.000781	CcSEcCtD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—urinary bladder cancer	3.07e-05	0.0023	CbGpPWpGaD
Nilutamide—Constipation—Epirubicin—urinary bladder cancer	3.04e-05	0.000774	CcSEcCtD
Nilutamide—Pain—Epirubicin—urinary bladder cancer	3.04e-05	0.000774	CcSEcCtD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—MYC—urinary bladder cancer	3.04e-05	0.00228	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	3.03e-05	0.00227	CbGpPWpGaD
Nilutamide—Body temperature increased—Methotrexate—urinary bladder cancer	3e-05	0.000764	CcSEcCtD
Nilutamide—Abdominal pain—Methotrexate—urinary bladder cancer	3e-05	0.000764	CcSEcCtD
Nilutamide—CYP2C8—Biological oxidations—GSTT1—urinary bladder cancer	2.99e-05	0.00224	CbGpPWpGaD
Nilutamide—Insomnia—Doxorubicin—urinary bladder cancer	2.98e-05	0.000757	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	2.96e-05	0.00222	CbGpPWpGaD
Nilutamide—Paraesthesia—Doxorubicin—urinary bladder cancer	2.95e-05	0.000752	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	2.95e-05	0.00222	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	2.94e-05	0.00221	CbGpPWpGaD
Nilutamide—Dyspnoea—Doxorubicin—urinary bladder cancer	2.93e-05	0.000746	CcSEcCtD
Nilutamide—Feeling abnormal—Epirubicin—urinary bladder cancer	2.93e-05	0.000746	CcSEcCtD
Nilutamide—Gastrointestinal pain—Epirubicin—urinary bladder cancer	2.91e-05	0.00074	CcSEcCtD
Nilutamide—Dyspepsia—Doxorubicin—urinary bladder cancer	2.9e-05	0.000737	CcSEcCtD
Nilutamide—CYP2C8—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	2.88e-05	0.00216	CbGpPWpGaD
Nilutamide—Decreased appetite—Doxorubicin—urinary bladder cancer	2.86e-05	0.000728	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	2.84e-05	0.000723	CcSEcCtD
Nilutamide—Constipation—Doxorubicin—urinary bladder cancer	2.81e-05	0.000716	CcSEcCtD
Nilutamide—Pain—Doxorubicin—urinary bladder cancer	2.81e-05	0.000716	CcSEcCtD
Nilutamide—Abdominal pain—Epirubicin—urinary bladder cancer	2.81e-05	0.000715	CcSEcCtD
Nilutamide—Body temperature increased—Epirubicin—urinary bladder cancer	2.81e-05	0.000715	CcSEcCtD
Nilutamide—AR—Androgen receptor signaling pathway—EGFR—urinary bladder cancer	2.75e-05	0.00207	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—HPGDS—urinary bladder cancer	2.75e-05	0.00206	CbGpPWpGaD
Nilutamide—Asthenia—Methotrexate—urinary bladder cancer	2.73e-05	0.000694	CcSEcCtD
Nilutamide—Feeling abnormal—Doxorubicin—urinary bladder cancer	2.71e-05	0.00069	CcSEcCtD
Nilutamide—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	2.69e-05	0.000685	CcSEcCtD
Nilutamide—Pruritus—Methotrexate—urinary bladder cancer	2.69e-05	0.000684	CcSEcCtD
Nilutamide—CYP2C19—Biological oxidations—GSTT1—urinary bladder cancer	2.67e-05	0.002	CbGpPWpGaD
Nilutamide—Body temperature increased—Doxorubicin—urinary bladder cancer	2.6e-05	0.000662	CcSEcCtD
Nilutamide—Abdominal pain—Doxorubicin—urinary bladder cancer	2.6e-05	0.000662	CcSEcCtD
Nilutamide—Diarrhoea—Methotrexate—urinary bladder cancer	2.6e-05	0.000662	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	2.58e-05	0.00193	CbGpPWpGaD
Nilutamide—CYP2C19—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	2.57e-05	0.00193	CbGpPWpGaD
Nilutamide—Asthenia—Epirubicin—urinary bladder cancer	2.55e-05	0.000649	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	2.54e-05	0.00191	CbGpPWpGaD
Nilutamide—Pruritus—Epirubicin—urinary bladder cancer	2.52e-05	0.00064	CcSEcCtD
Nilutamide—Dizziness—Methotrexate—urinary bladder cancer	2.51e-05	0.000639	CcSEcCtD
Nilutamide—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	2.51e-05	0.00188	CbGpPWpGaD
Nilutamide—Diarrhoea—Epirubicin—urinary bladder cancer	2.43e-05	0.000619	CcSEcCtD
Nilutamide—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	2.43e-05	0.00183	CbGpPWpGaD
Nilutamide—Vomiting—Methotrexate—urinary bladder cancer	2.42e-05	0.000615	CcSEcCtD
Nilutamide—AR—Generic Transcription Pathway—ESR2—urinary bladder cancer	2.41e-05	0.00181	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	2.41e-05	0.00181	CbGpPWpGaD
Nilutamide—Rash—Methotrexate—urinary bladder cancer	2.4e-05	0.00061	CcSEcCtD
Nilutamide—Dermatitis—Methotrexate—urinary bladder cancer	2.39e-05	0.000609	CcSEcCtD
Nilutamide—Headache—Methotrexate—urinary bladder cancer	2.38e-05	0.000606	CcSEcCtD
Nilutamide—Asthenia—Doxorubicin—urinary bladder cancer	2.36e-05	0.000601	CcSEcCtD
Nilutamide—Dizziness—Epirubicin—urinary bladder cancer	2.35e-05	0.000598	CcSEcCtD
Nilutamide—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	2.35e-05	0.00176	CbGpPWpGaD
Nilutamide—Pruritus—Doxorubicin—urinary bladder cancer	2.33e-05	0.000592	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—CCND1—urinary bladder cancer	2.3e-05	0.00173	CbGpPWpGaD
Nilutamide—Vomiting—Epirubicin—urinary bladder cancer	2.26e-05	0.000575	CcSEcCtD
Nilutamide—Nausea—Methotrexate—urinary bladder cancer	2.26e-05	0.000574	CcSEcCtD
Nilutamide—Diarrhoea—Doxorubicin—urinary bladder cancer	2.25e-05	0.000573	CcSEcCtD
Nilutamide—Rash—Epirubicin—urinary bladder cancer	2.24e-05	0.000571	CcSEcCtD
Nilutamide—Dermatitis—Epirubicin—urinary bladder cancer	2.24e-05	0.00057	CcSEcCtD
Nilutamide—Headache—Epirubicin—urinary bladder cancer	2.23e-05	0.000567	CcSEcCtD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	2.22e-05	0.00167	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—PTEN—urinary bladder cancer	2.22e-05	0.00167	CbGpPWpGaD
Nilutamide—Dizziness—Doxorubicin—urinary bladder cancer	2.18e-05	0.000554	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	2.16e-05	0.00162	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—EP300—urinary bladder cancer	2.12e-05	0.00159	CbGpPWpGaD
Nilutamide—Nausea—Epirubicin—urinary bladder cancer	2.11e-05	0.000538	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	2.11e-05	0.00158	CbGpPWpGaD
Nilutamide—Vomiting—Doxorubicin—urinary bladder cancer	2.09e-05	0.000532	CcSEcCtD
Nilutamide—Rash—Doxorubicin—urinary bladder cancer	2.07e-05	0.000528	CcSEcCtD
Nilutamide—Dermatitis—Doxorubicin—urinary bladder cancer	2.07e-05	0.000527	CcSEcCtD
Nilutamide—CYP2C8—Biological oxidations—GSTP1—urinary bladder cancer	2.07e-05	0.00155	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	2.06e-05	0.00155	CbGpPWpGaD
Nilutamide—Headache—Doxorubicin—urinary bladder cancer	2.06e-05	0.000525	CcSEcCtD
Nilutamide—CYP2C8—Metapathway biotransformation—GSTP1—urinary bladder cancer	2.04e-05	0.00153	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	1.99e-05	0.00149	CbGpPWpGaD
Nilutamide—Nausea—Doxorubicin—urinary bladder cancer	1.95e-05	0.000497	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	1.91e-05	0.00143	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—GSTM1—urinary bladder cancer	1.9e-05	0.00143	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—GSTM1—urinary bladder cancer	1.88e-05	0.00141	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—NCOR1—urinary bladder cancer	1.86e-05	0.0014	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—GSTP1—urinary bladder cancer	1.85e-05	0.00139	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—MYC—urinary bladder cancer	1.85e-05	0.00138	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	1.84e-05	0.00138	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	1.84e-05	0.00138	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—GSTP1—urinary bladder cancer	1.82e-05	0.00137	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	1.81e-05	0.00136	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—EGFR—urinary bladder cancer	1.8e-05	0.00135	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.75e-05	0.00132	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.71e-05	0.00128	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—KRAS—urinary bladder cancer	1.7e-05	0.00128	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—GSTM1—urinary bladder cancer	1.7e-05	0.00128	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	1.69e-05	0.00127	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—GSTM1—urinary bladder cancer	1.68e-05	0.00126	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	1.67e-05	0.00126	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	1.66e-05	0.00125	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	1.55e-05	0.00116	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.53e-05	0.00115	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	1.53e-05	0.00115	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	1.52e-05	0.00114	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.5e-05	0.00112	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—ESR1—urinary bladder cancer	1.46e-05	0.0011	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.42e-05	0.00107	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.41e-05	0.00106	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—PPARG—urinary bladder cancer	1.33e-05	0.001	CbGpPWpGaD
Nilutamide—AR—Gene Expression—SMC1A—urinary bladder cancer	1.33e-05	0.000998	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—CREBBP—urinary bladder cancer	1.28e-05	0.00096	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GSTZ1—urinary bladder cancer	1.27e-05	0.000952	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.26e-05	0.000942	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GSTO2—urinary bladder cancer	1.2e-05	0.000903	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—NAT1—urinary bladder cancer	1.2e-05	0.000903	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	1.18e-05	0.000888	CbGpPWpGaD
Nilutamide—AR—Gene Expression—ESR2—urinary bladder cancer	1.16e-05	0.00087	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	1.13e-05	0.00085	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—UGT2B7—urinary bladder cancer	1.1e-05	0.000826	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	1.07e-05	0.000806	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—NAT1—urinary bladder cancer	1.07e-05	0.000806	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	1.06e-05	0.000793	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	1.03e-05	0.000775	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	9.91e-06	0.000744	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	9.82e-06	0.000737	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	9.79e-06	0.000735	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—NAT1—urinary bladder cancer	9.79e-06	0.000735	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	9.63e-06	0.000723	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	9.36e-06	0.000702	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	9.12e-06	0.000684	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	8.96e-06	0.000672	CbGpPWpGaD
Nilutamide—AR—Gene Expression—NCOR1—urinary bladder cancer	8.95e-06	0.000672	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	8.84e-06	0.000664	CbGpPWpGaD
Nilutamide—AR—Gene Expression—ERCC2—urinary bladder cancer	8.41e-06	0.000631	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	8.35e-06	0.000627	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	8.14e-06	0.000611	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	8.06e-06	0.000605	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	7.61e-06	0.000571	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—MYC—urinary bladder cancer	7.59e-06	0.00057	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	7.42e-06	0.000557	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	7.31e-06	0.000549	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—TYMP—urinary bladder cancer	7.29e-06	0.000547	CbGpPWpGaD
Nilutamide—AR—Gene Expression—ESR1—urinary bladder cancer	7.03e-06	0.000528	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	7e-06	0.000525	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—NAT2—urinary bladder cancer	6.59e-06	0.000495	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	6.53e-06	0.00049	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—TYMP—urinary bladder cancer	6.51e-06	0.000488	CbGpPWpGaD
Nilutamide—AR—Gene Expression—PPARG—urinary bladder cancer	6.41e-06	0.000481	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	6.25e-06	0.000469	CbGpPWpGaD
Nilutamide—AR—Gene Expression—CREBBP—urinary bladder cancer	6.16e-06	0.000462	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.95e-06	0.000447	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—TYMP—urinary bladder cancer	5.93e-06	0.000445	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—NAT2—urinary bladder cancer	5.88e-06	0.000442	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.7e-06	0.000428	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—RRM2—urinary bladder cancer	5.69e-06	0.000427	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—NAT2—urinary bladder cancer	5.36e-06	0.000403	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	5.27e-06	0.000395	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—ENO2—urinary bladder cancer	5.27e-06	0.000395	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.24e-06	0.000393	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	5.11e-06	0.000384	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—RRM2—urinary bladder cancer	5.08e-06	0.000381	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.03e-06	0.000378	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—ENO2—urinary bladder cancer	4.7e-06	0.000353	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	4.7e-06	0.000353	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.68e-06	0.000351	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—RRM2—urinary bladder cancer	4.63e-06	0.000348	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	4.56e-06	0.000342	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.49e-06	0.000337	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	4.29e-06	0.000322	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—ENO2—urinary bladder cancer	4.29e-06	0.000322	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.26e-06	0.00032	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—NQO1—urinary bladder cancer	4.25e-06	0.000319	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	4.16e-06	0.000312	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.12e-06	0.000309	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.1e-06	0.000307	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—NQO1—urinary bladder cancer	3.79e-06	0.000285	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.68e-06	0.000276	CbGpPWpGaD
Nilutamide—AR—Gene Expression—MYC—urinary bladder cancer	3.66e-06	0.000274	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.59e-06	0.00027	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	3.54e-06	0.000266	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—NQO1—urinary bladder cancer	3.46e-06	0.000259	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.43e-06	0.000257	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.35e-06	0.000252	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—TYMS—urinary bladder cancer	3.29e-06	0.000247	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	3.26e-06	0.000244	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	3.26e-06	0.000244	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.21e-06	0.000241	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	3.16e-06	0.000237	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GPX1—urinary bladder cancer	3.12e-06	0.000234	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	3.06e-06	0.00023	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.06e-06	0.00023	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—TYMS—urinary bladder cancer	2.94e-06	0.000221	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.93e-06	0.00022	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	2.91e-06	0.000218	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	2.91e-06	0.000218	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	2.88e-06	0.000216	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	2.88e-06	0.000216	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.79e-06	0.000209	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GPX1—urinary bladder cancer	2.78e-06	0.000209	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	2.73e-06	0.000205	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—TYMS—urinary bladder cancer	2.68e-06	0.000201	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	2.65e-06	0.000199	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	2.65e-06	0.000199	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	2.57e-06	0.000193	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GPX1—urinary bladder cancer	2.54e-06	0.00019	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	2.49e-06	0.000187	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	2.34e-06	0.000176	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PPARG—urinary bladder cancer	2.33e-06	0.000175	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	2.24e-06	0.000168	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PPARG—urinary bladder cancer	2.08e-06	0.000156	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	2e-06	0.00015	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.9e-06	0.000143	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	1.84e-06	0.000138	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.82e-06	0.000137	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.64e-06	0.000123	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PTEN—urinary bladder cancer	1.6e-06	0.00012	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—EP300—urinary bladder cancer	1.53e-06	0.000115	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.49e-06	0.000112	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PTEN—urinary bladder cancer	1.43e-06	0.000107	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—EP300—urinary bladder cancer	1.36e-06	0.000102	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.3e-06	9.78e-05	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.24e-06	9.32e-05	CbGpPWpGaD
